
YLF-466D
CAS No. 1273323-67-3
YLF-466D( —— )
Catalog No. M33176 CAS No. 1273323-67-3
YLF-466D (C24) is a novel AMPK activator that inhibits platelet aggregation.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 79 | In Stock |
![]() ![]() |
5MG | 121 | In Stock |
![]() ![]() |
10MG | 188 | In Stock |
![]() ![]() |
25MG | 321 | In Stock |
![]() ![]() |
50MG | 459 | In Stock |
![]() ![]() |
100MG | 621 | In Stock |
![]() ![]() |
500MG | 1233 | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameYLF-466D
-
NoteResearch use only, not for human use.
-
Brief DescriptionYLF-466D (C24) is a novel AMPK activator that inhibits platelet aggregation.
-
DescriptionYLF-466D is a newly developed AMPK activator, which inhibits platelet aggregation.
-
In VitroThe effect of YLF-466D on platelet AMPK and aggregation are examined to test whether YLF-466D can stimulate AMPK in platelets and thereby suppress aggregation. Platelet AMPK is activated by YLF-466D, which is confirmed with activation-dependent phosphorylation at Thr172. Consistent with this result, YLF-466D inhibits platelet aggregation induced by thrombin. Such inhibition is observed in the aggregation elicited by ADP and collagen as well as thrombin, indicating that the antiaggregatory effect of YLF-466D is not platelet-agonist specific but common, regardless of agonist type. All the effects on AMPK and aggregation are concentration-dependent with the highest efficacy at 150 μM. IC50 against thrombin-, ADP- and collagen-induced aggreation are approximately 84, 55 and 87 μM, respectively.
-
In Vivo——
-
Synonyms——
-
PathwayMembrane Transporter/Ion Channel
-
TargetAMPK
-
RecptorAMPK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1273323-67-3
-
Formula Weight465.93
-
Molecular FormulaC29H20ClNO3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 100 mg/mL (214.62 mM )
-
SMILESOC(=O)c1cccc(CN2C(=O)\C(=C(/c3ccccc3)c3ccc(Cl)cc3)c3ccccc23)c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Liu Y, et al. Antiplatelet effect of a newly developed AMP-activated protein kinase activator YLF-466D. Eur J Pharmacol. 2015 Aug 5;760:81-7.?
molnova catalog



related products
-
Cimiracemoside C
Cimiracemoside C is an active component of Cimicifuga racemosa. It activates AMPK and has the potential activity against diabetes.
-
AMAROGENTIN
Amarogentin is mainly extracted from Swertia and Gentiana roots. It plays cemopreventive/therapeutic role during liver carcinogenesis through modulation of cell cycle and apoptosis
-
Tectochrysin
Tectochrysin leads to apoptotic cell death in NSCLC cells through activation of DR3 and Fas expression via inhibition of STAT3 phosphorylation.